PSA response as a sign of treatment success in prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has been confirmed by a biopsy and has spread to other parts of the body.
- You have an ECOG performance status of 0, 1, or 2 (meaning you are able to care for yourself).
- You have had imaging scans (like CT, bone scan, or PET scan) to see where the cancer has spread.
- You have had your PSA level measured before starting hormone therapy and again after about six months.
- You are currently taking or have completed treatment with one of these drugs: abiraterone, apalutamide, darolutamide, or enzalutamide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
This study looks at how levels of common prostate cancer hormone treatments (abiraterone, apalutamide, darolutamide, or enzalutamide) stay in your blood over time. By checking drug levels, doctors hope to personalize dosing to make treatment safer and more effective.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.